Eli Lilly and Co plans this year to begin a new late-stage trial of solanezumab, its experimental treatment for Alzheimer’s disease that failed in earlier testing to significantly slow progression of the memory-robbing disease. Brigham and Women’s Hospital is helping coordinate the three-year study.
